NY-Z-CAPITAL-GROUP
2.3.2023 06:34:19 CET | Business Wire | Press release
Z Capital Group, L.L.C. ("ZCG") today announced it has signed as a Team Partner to Scuderia Ferrari for the 2023 season. Through this partnership, ZCG’s logo will appear on the SF-23 livery starting at the Bahrain Grand Prix, the first round of the 2023 Formula 1 World Championship.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005697/en/
Z Capital Group announced it has signed as a Team Partner to Scuderia Ferrari for the 2023 season (Graphic: Business Wire)
“ZCG shares Scuderia Ferrari’s steadfast commitment to innovation and excellence,” said James Zenni, Founder, President and Chief Executive Officer of ZCG. “This is a unique opportunity to partner with one of the sport’s most iconic brands and to engage with millions of fans and Formula 1 enthusiasts around the world. Ferrari has been a central player throughout Formula 1’s long and storied history. We are thrilled to support the team as it enters the 2023 season in pursuit of its record 17th championship.”
“Operating at the highest level in the world of motorsport we are always looking for partners who share our global perspective and dedication to unparalleled performance,” said Lorenzo Giorgetti, Chief Racing Revenue Officer of Scuderia Ferrari. “We are pleased to welcome ZCG as a Team Partner and can’t wait to build on this partnership together in the year ahead.”
Formula 1, already one of the most exciting and prestigious motorsport competitions in the world, has experienced a surge in popularity in recent years. In the United States alone, the 2022 season averaged nearly 300,000 more viewers across each of its 22 Grand Prix weekends than the prior season. As Formula 1 continues to grow in popularity across the globe, this partnership will align ZCG with one of the sport’s most storied names.
2023 will be ZCG’s second year supporting the growth of Formula 1 as a Team Partner and its first year working with Scuderia Ferrari.
About ZCG
ZCG is an industry leader comprised of private markets asset management, business consulting services, technology development and solutions.
For almost 30 years, ZCG Principals have invested approximately $30 billion and have industry leading track records in private equity and credit.
ZCG has approximately $6.5B of AUM in asset management and its investors are some of the largest and most sophisticated global institutional investors including pension funds, endowments, foundations, sovereign wealth funds, central banks, and insurance companies.
ZCG has a global team comprised of nearly 400 professionals. For more information, please visit www.zcg.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005697/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Unveils AI-Native Platform for IT Financial Management30.4.2026 17:00:00 CEST | Press release
Brightfin clients drive their businesses forward with the first AI Native Cost Optimization Platform Brightfin, the only ITFM and Technology Expense Management solution built natively on ServiceNow, today announced an AI-Native architecture that fundamentally improves how organizations manage IT spend. Rather than bolting AI onto legacy systems, Brightfin has engineered intelligence from the ground up - starting with the data, building contextual awareness on top of it, and delivering AI agents that speak the language of IT finance. Brightfin’s unified budget-to-billing data model creates a stable, governed foundation that connects contracts, invoices, inventory, and budgets into a single source of truth - something no external ITFM tool or native platform module can replicate. This is a structured financial backbone purpose-built for enterprise IT spend, and it’s what makes everything above it possible. A context-aware, AI-Native, intelligence layer understands relationships across th
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 15:22:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et
Experian Announces Agent Trust to Power Trusted AI Driven Commerce30.4.2026 15:00:00 CEST | Press release
First-of-its-kind human-to-agent binding service for secure AI-driven commerce, developed with a growing ecosystem of agentic commerce collaborators, including Visa, Cloudflare and Skyfire Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430719198/en/ Experian Announces Agent Trust to Power Trusted AI Driven Commerce. As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust addresses this challenge through a new “Kn
Meet the AI-powered fan companion: TGR Haas F1 Team RaceMate powered by Infobip30.4.2026 15:00:00 CEST | Press release
New always-on conversational agent with team race intelligence, team insights, and interactive experiences powered by Infobip AgentOS Global AI-first cloud communications platform Infobip and TGR Haas F1 team are launching ‘TGR Haas F1 Team RaceMate powered by Infobip’, an AI-powered conversational fan companion on Apple Messages for Business and WhatsApp Business Platform. Always-on and always available, it delivers race intelligence for TGR Haas F1 Team: team race intelligence, grid positions, qualifying outcomes, sprint results, and full session schedules. The AI agent tracks drivers Ollie Bearman and Esteban Ocon with their individual championship standings and performance data in conversational format. The agent draws from a knowledge base covering driver biographies, team history, and circuit data, adapting to each user's knowledge level. Every interaction begins with a schedule check, ensuring fans always know what's happening right now. It proactively surfaces relevant informat
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom